中国组织工程研究与临床康复
中國組織工程研究與臨床康複
중국조직공정연구여림상강복
JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH
2009年
39期
7743-7746
,共4页
脑血管病%支架%治疗%并发症%生物相容
腦血管病%支架%治療%併髮癥%生物相容
뇌혈관병%지가%치료%병발증%생물상용
目的:阐述脑血管支架的治疗进展,评价其与宿主间的生物相容性.方法:由第一作者用计算机检索中国期刊全文数据库(CNKI: 1989/2009)和Medline database(1989/2009)数据库,检索词分别为"脑血管病,支架,治疗"和"cerebrovascular disease, stent,therapy",语言分别设定为中文和英文.共检索到53篇文章,按纳入和排除标准对文献进行筛选,共纳入22篇文章.分别以脑血管支架的治疗进展,脑血管支架置入的并发症和脑血管支架的生物相容性3方面进行归纳和总结,探讨各类不同支架的生物相容性.结果:脑血管支架主要应用于脑动脉狭窄、脑动脉瘤、静脉窦狭窄或血栓治疗.置入并发症主要有颈动脉窦反应,高灌注综合征,脑血管痉挛、血栓形成、再狭窄等.支架置入前对狭窄部位的充分预扩是防止支架变形和移位的关键.血管支架置入后发生再狭窄的影响因素与支架种类有关.在各种脑血管支架中,金属支架易促进血栓的形成.聚合物支架与血管壁的相容性好于金属支架,可避免后期的内膜增殖.涂层支架可通过特殊涂覆技术包被于金属支架表面,抑制血小板的聚集.药物支架置入体内后,药物能够持续高浓度的释放,药物能够在"靶位"达到有效治疗浓度,能够有效的预防支架内置入后的再狭窄.结论:脑血管支架置入可作为脑血管病的一种重要治疗手段.金属支架的生物相容性较差,聚合物支架、涂层支架和药物支架的生物相容性较好.
目的:闡述腦血管支架的治療進展,評價其與宿主間的生物相容性.方法:由第一作者用計算機檢索中國期刊全文數據庫(CNKI: 1989/2009)和Medline database(1989/2009)數據庫,檢索詞分彆為"腦血管病,支架,治療"和"cerebrovascular disease, stent,therapy",語言分彆設定為中文和英文.共檢索到53篇文章,按納入和排除標準對文獻進行篩選,共納入22篇文章.分彆以腦血管支架的治療進展,腦血管支架置入的併髮癥和腦血管支架的生物相容性3方麵進行歸納和總結,探討各類不同支架的生物相容性.結果:腦血管支架主要應用于腦動脈狹窄、腦動脈瘤、靜脈竇狹窄或血栓治療.置入併髮癥主要有頸動脈竇反應,高灌註綜閤徵,腦血管痙攣、血栓形成、再狹窄等.支架置入前對狹窄部位的充分預擴是防止支架變形和移位的關鍵.血管支架置入後髮生再狹窄的影響因素與支架種類有關.在各種腦血管支架中,金屬支架易促進血栓的形成.聚閤物支架與血管壁的相容性好于金屬支架,可避免後期的內膜增殖.塗層支架可通過特殊塗覆技術包被于金屬支架錶麵,抑製血小闆的聚集.藥物支架置入體內後,藥物能夠持續高濃度的釋放,藥物能夠在"靶位"達到有效治療濃度,能夠有效的預防支架內置入後的再狹窄.結論:腦血管支架置入可作為腦血管病的一種重要治療手段.金屬支架的生物相容性較差,聚閤物支架、塗層支架和藥物支架的生物相容性較好.
목적:천술뇌혈관지가적치료진전,평개기여숙주간적생물상용성.방법:유제일작자용계산궤검색중국기간전문수거고(CNKI: 1989/2009)화Medline database(1989/2009)수거고,검색사분별위"뇌혈관병,지가,치료"화"cerebrovascular disease, stent,therapy",어언분별설정위중문화영문.공검색도53편문장,안납입화배제표준대문헌진행사선,공납입22편문장.분별이뇌혈관지가적치료진전,뇌혈관지가치입적병발증화뇌혈관지가적생물상용성3방면진행귀납화총결,탐토각류불동지가적생물상용성.결과:뇌혈관지가주요응용우뇌동맥협착、뇌동맥류、정맥두협착혹혈전치료.치입병발증주요유경동맥두반응,고관주종합정,뇌혈관경련、혈전형성、재협착등.지가치입전대협착부위적충분예확시방지지가변형화이위적관건.혈관지가치입후발생재협착적영향인소여지가충류유관.재각충뇌혈관지가중,금속지가역촉진혈전적형성.취합물지가여혈관벽적상용성호우금속지가,가피면후기적내막증식.도층지가가통과특수도복기술포피우금속지가표면,억제혈소판적취집.약물지가치입체내후,약물능구지속고농도적석방,약물능구재"파위"체도유효치료농도,능구유효적예방지가내치입후적재협착.결론:뇌혈관지가치입가작위뇌혈관병적일충중요치료수단.금속지가적생물상용성교차,취합물지가、도층지가화약물지가적생물상용성교호.
OBJECTIVE: To investigate therapeutic progress of cerebral intravascular stent, and to evaluate biocompatlbility with host.METHODS: Articles were collected from CNKI and Medline database with the keywords of "cerebrovascular disease, stent, and therapy" in both Chinese and English from 1989 to 2009. Among 53 articles, 22 were included according to inclusion and exclusion criteria; while the included articles were summarized in the fields of therapeutic progress of cerebral intravascular stent,complication following cerebral intravascular stent implantation, and biocompatlbility of cerebral intravascular stent in order to investigate the biocompatibility of various stents.RESULTS: Cerebral intravascular stent was mainly used to treat cerebral artery stenosis, cerebral aneurysm, venous sinus stenosis, and thrombus. Complications following cerebral intravascular stent implantation included carotid sinus syndrome,hypertransfusion syndrome, cerebral angiospasm, thrombosis, and restenosis. Pre-enlargement prior to implantation in the stenotic region played an important role in avoiding deformation and displacement of stent. Restenosis correlated to stent types following cerebral intravascular stent implantation. For example, metal stent could promote thrombosis; however, polymer which had an excellent biocompatibility to vessel wall was superior to metal stent, thus it could prevent endomembrane proliferation following implantation. Metal-coated stent could inhibit aggregation of platelet; additionally, drug stent could effectively prevent restenosis via high-concentration drug release for a long term.CONCLUSION: Cerebral intravascular stent is considered as an ideal tool to treat cerebrovascular disease. Metal stent has a poor compatibility, but polymer stent, coating stent, and drug stent have a good compatibility.